The role of C-reactive protein as a marker for cardiovascular risk associated with antiretroviral therapy in HIV-infected patients

Mar Masiá(Universidad de Alcalá), Félix Gutiérrez(Universitat de Miguel Hernández d'Elx), Enrique Bernal(Honeywell (United States)), M. Graells(Hospital Marina Baixa), Ildefonso Hernández‐Aguado(Universitat de Miguel Hernández d'Elx), Sergio Padilla(Hospital General Universitario de Elche), María Almenar(Hospital Marina Baixa), Juan Molina(Hospital Marina Baixa), Inmaculada Jarrín(Instituto de Salud Carlos III)
Atherosclerosis
October 18, 2006
10.1016/j.atherosclerosis.2006.09.013
Cited by 57

Related Papers

Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy
|JAMA|2016|1.4k
Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study
|The Lancet|2019|1k
Association Between Administration of IL-6 Antagonists and Mortality Among Patients Hospitalized for COVID-19
|JAMA|2021|728
Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies
|The Lancet HIV|2023|506
Incidence and Severity of COVID-19 in HIV-Positive Persons Receiving Antiretroviral Therapy
|Annals of Internal Medicine|2020|342